Nuvectis Pharma(NASDAQ) NVCT

Nuvectis creates targeted medicines to treat serious types of cancer. These drugs help patients with medical needs that existing treatments miss. The company focuses on specific genetic changes found in tumor cells.

Fighting Cancer With Precision

• NXP900: Drug candidate that blocks kinases, which are enzymes that help cancers grow and spread.
• NXP800: Oral medicine designed to block a specific pathway that tumors use to survive under stress.

Strategic Steps Forward

• Licensed exclusive world-wide rights for NXP900 from the University of Edinburgh in August 2021.
• Entered a licensing agreement with CRT Pioneer Fund to develop NXP800 for various cancer treatments.
• Initiated the Phase 1b expansion study—a stage testing safety and effectiveness—for NXP900 in August 2025.
• Launched a clinical trial combining NXP900 with the lung cancer drug osimertinib in December 2025.
• Completed a public offering in February 2025 that generated $14 million in net proceeds.

How They Operate

Nuvectis uses precision medicine to target proteins that are active in tumors but inactive in healthy cells. The company maintains a small workforce of 12 employees to manage research and clinical trial oversight.

By the Numbers

• Operating loss was $6.26 million in Q1 2026, deepening 12.4% year-over-year.
• Net loss reached $6.05 million in Q1 2026, worsening 13.5% from Q1 2025.
• Free cash flow hit negative $6.51 million in Q1 2026, a 56% deepening from the prior year.
• Cash and cash equivalents totaled $25.13 million as of March 31, 2026.

Bottom Line

Nuvectis has transitioned into a clinical-stage biotechnology firm testing multiple precision therapies for serious cancers. Its progress relies on successfully moving drug candidates through expensive human trials without current product revenue.